-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Oruka Therapeutics, Raises Price Target to $50

Benzinga·03/13/2026 19:45:12
Listen to the news
Barclays analyst Etzer Darout maintains Oruka Therapeutics (NASDAQ:ORKA) with a Overweight and raises the price target from $48 to $50.